Other Pharmaceuticals - Eastern Africa

Eastern Africa

Highlights

The market of Other Pharmaceuticals market in Eastern Africa is expected to witness a substantial growth in revenue, projected to reach US$752.10m in 2024.
This growth is expected to continue with an annual growth rate of 4.35% from 2024 to 2029, resulting in a market volume of US$930.50m by 2029.
When compared globally, it is worth noting that United States will generate the highest revenue in this market, with an estimated value of US$260.50bn in 2024.
Eastern Africa's market for other pharmaceuticals is witnessing a surge in demand due to increasing healthcare awareness and government initiatives.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Pharmaceuticals market in Eastern Africa has shown significant growth in recent years.

Customer preferences: Customers in Eastern Africa are increasingly seeking out alternative forms of medicine, including traditional herbal remedies, which has contributed to the growth of the Other Pharmaceuticals market. Additionally, the rising prevalence of chronic diseases such as diabetes and hypertension has increased demand for pharmaceutical products in the region.

Trends in the market: Kenya has emerged as a key market for Other Pharmaceuticals in Eastern Africa due to its large population and relatively developed healthcare system. The country has seen increasing investment in the pharmaceutical sector, particularly in the production of generic drugs. Tanzania and Uganda are also growing markets for Other Pharmaceuticals, driven by rising demand for affordable healthcare and increasing investment in healthcare infrastructure.

Local special circumstances: The high cost of imported pharmaceutical products has led to the growth of local production in some countries in the region. For example, the Kenyan government has implemented policies to support local pharmaceutical production, which has led to the establishment of several local pharmaceutical companies. Additionally, the prevalence of counterfeit drugs in the region has led to increased demand for locally produced pharmaceutical products.

Underlying macroeconomic factors: The growth of the Other Pharmaceuticals market in Eastern Africa is supported by several macroeconomic factors, including increasing investment in healthcare infrastructure, rising disposable incomes, and a growing population. However, challenges such as weak regulatory frameworks and limited access to financing for local pharmaceutical companies could hinder future growth in the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.